机构：[1]Center for Diabetes and Metabolism Research, Division of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[3]School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200240, China.[4]Bioimaging Center, Shanghai Synchrotron Radiation Facility, Zhangjiang Laboratory, The Interdisciplinary Research Center, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, China.[5]The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, SE-17176 Stockholm, Sweden.[6]Core facility of West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[7]The Center for Growth, Metabolism and Aging, The College of Life Sciences, Sichuan University, Chengdu 610041, China.[8]Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW 2145, Australia.[9]Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre and West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[10]Division of Endocrinology and Metabolism, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.四川大学华西医院
Cytokine immunotherapy represents an attractive strategy to stimulate robust immune responses for renal injury repair in ischemic acute kidney injury (AKI). However, its clinical application is hindered by its nonspecificity to kidney, short circulation half-life, and severe side effects. An ideal cytokine immunotherapy for AKI requires preferential delivery of cytokines with accurate dosage to the kidney and sustained-release of cytokines to stimulate the immune responses. Herein, we developed a DNA nanoraft cytokine by precisely arranging interleukin-33 (IL-33) nanoarray on rectangle DNA origami, through which IL-33 can be preferentially delivered to the kidney for alleviation of AKI. A nanoraft carrying precisely quantified IL-33 predominantly accumulated in the kidney for up to 48 h. Long-term sustained-release of IL-33 from nanoraft induced rapid expansion of type 2 innate lymphoid cells (ILC 2s) and regulatory T cells (Tregs) and achieved better treatment efficiency compared to free IL-33 treatment. Thus, our study demonstrates that a nanoraft can serve as a structurally well-defined delivery platform for cytokine immunotherapy in ischemic AKI and other renal diseases.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|1 区材料科学
小类|1 区化学综合1 区物理化学1 区纳米科技1 区材料科学：综合
最新[2023]版：
大类|1 区材料科学
小类|1 区化学：综合1 区物理化学1 区材料科学：综合1 区纳米科技
第一作者：
第一作者机构：[1]Center for Diabetes and Metabolism Research, Division of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Li Wei,Wang Chengshi,Lv Hui,et al.A DNA Nanoraft-Based Cytokine Delivery Platform for Alleviation of Acute Kidney Injury.[J].ACS nano.2021,doi:10.1021/acsnano.1c07270.
APA：
Li Wei,Wang Chengshi,Lv Hui,Wang Zhenghao,Zhao Meng...&Berggren Per-Olof.(2021).A DNA Nanoraft-Based Cytokine Delivery Platform for Alleviation of Acute Kidney Injury..ACS nano,,
MLA：
Li Wei,et al."A DNA Nanoraft-Based Cytokine Delivery Platform for Alleviation of Acute Kidney Injury.".ACS nano .(2021)
材料科学